DEBIGLIP 100 SR Tablet 15's

15 Tablet(s) in a Strip Mkt: Leeford Healthcare Ltd (Generics) Country of Origin: India
Diabetes Rx required
₹124.18
MRP ₹234.30 Save 47 %
Inclusive of all taxes
DEBIGLIP 100 SR Tablet 15's ₹124.18
MRP ₹234.30 Save 47 %
Medicine requires valid prescription GOT IT
Request and get upto 20% OFF on high priced medicines. Request Now

Expiry on or after

Pincode

Happy Customers 9M+ Happy Customers
Authentic Products 100% Authentic
Best Quality Quality Checked Products
Showing 46 substitutes for DEBIGLIP 100 SR Tablet 15's
ALTERNATE BRANDS
GLIPY OD 100 SR Tablet 15's
Prescription Diabetes Rx required
MRP ₹ 180.00
Get this at ₹ 144.00 >
VSMALL OD 100 Tablet 10's
Prescription Diabetes Rx required
MRP ₹ 110.00
Get this at ₹ 88.00 >
VILDANA SR 100 Tablet 10's
Prescription Diabetes Rx required
MRP ₹ 130.00
Get this at ₹ 104.00 >
Show more

Introduction About DEBIGLIP 100 SR TABLET

DEBIGLIP 100 SR TABLET is used in adults to manage type 2 diabetes which helps to control the blood sugar levels when diet and exercise becomes insufficient to control the disease. It contains Vildagliptin which belongs to group of medicines called Oral Anti-diabetics.

Take DEBIGLIP 100 SR TABLET as advised by your physician. Do not crush or chew DEBIGLIP 100 SR TABLET. Swallow the medicine with a glass of water.

Along management with DEBIGLIP 100 SR TABLET, your doctor might advise you to follow the diet and/or exercise which is beneficial. Avoid consumption of alcohol because it might lead to low blood glucose levels. Before taking DEBIGLIP 100 SR TABLET, inform your doctor if you are on dialysis or have diabetic ketoacidosis (serious complication of diabetes), pancreatic disease, heart failure and liver or kidney disease.

DEBIGLIP 100 SR TABLET is not recommended for use in pregnant and breast-feeding women, which is also not recommended for use in children and adolescents (aged below 18 years). It should be used with caution in elderly patients (aged 65 years and above).

The side effects of taking DEBIGLIP 100 SR TABLET are dizziness, headache, joint pain and constipation.

Uses Of DEBIGLIP 100 SR TABLET

How DEBIGLIP 100 SR TABLET Works

DEBIGLIP 100 SR TABLET controls blood glucose level by acting on the pancreas to produce more insulin and less glucagon which leads to low production of blood sugar levels resulting in controlled blood glucose levels.

How to use DEBIGLIP 100 SR TABLET

  • Take DEBIGLIP 100 SR TABLET as advised by your physician.
  • Do not crush or chew DEBIGLIP 100 SR TABLET.
  • Swallow the medicine with a glass of water.
  • Your doctor will decide the correct dose and duration for you depending upon your age, body weight and disease condition.

Side Effects Of DEBIGLIP 100 SR TABLET

Common Side Effects of DEBIGLIP 100 SR TABLET:

  • Dizziness
  • Headache
  • Blurred vision
  • Constipation
  • Nausea, vomiting
  • Diarrhea
  • rashes

Stop taking DEBIGLIP 100 SR TABLET and contact your doctor immediately if you experience any of the following side effects:

  • Signs of liver disease (hepatitis) such as loss of appetite or dark-colored urine, yellow skin and eyes, nausea
  • Signs of inflammation of the pancreas such as severe and persistent pain in the abdomen (stomach area), nausea and vomiting

Warning & Precautions

Pregnancy

Contraindicated

DEBIGLIP 100 SR TABLET is not recommended for use in pregnant women.

Breastfeeding

Contraindicated

DEBIGLIP 100 SR TABLET is not recommended for use in breastfeeding women or women who plan to breast-feed.

Driving and Using Machines

Use with Caution

Do not drive or operate any machines if you feel dizziness after taking DEBIGLIP 100 SR TABLET.

Alcohol

Consult your doctor

Avoid consumption of alcohol while taking DEBIGLIP 100 SR TABLET because it might lead to hypoglycemia (lowering of blood glucose levels).

Kidney

Use with Caution

DEBIGLIP 100 SR TABLET should be used with caution in patients with moderate or severe kidney disease and in patients who are undergoing dialysis.

Liver

Use with Caution

DEBIGLIP 100 SR TABLET should be used with caution in patients with liver disease.

Allergy

Contraindicated

Do not take DEBIGLIP 100 SR TABLET if you are allergic to Vildagliptin or any other ingredients of this medicine.

Heart Disease

Use with Caution

DEBIGLIP 100 SR TABLET should be used with caution in patients suffering from heart failure.

Use In Pediatrics

Contraindicated

DEBIGLIP 100 SR TABLET is not recommended for use in children and adolescents up to 18 years of age.

Use In Geriatrics

Use with Caution

DEBIGLIP 100 SR TABLET should be used with caution in elderly patients (aged 65 years and above).

Others

Before taking DEBIGLIP 100 SR TABLET, inform your doctor if you:

  • Have type 1 diabetes (i.e. your body does not produce insulin)
  • Have a condition called diabetic ketoacidosis (serious complication of diabetes)
  • Have intolerance to certain sugars
  • Had or have a disease of the pancreas

Interactions

A. Drug-Drug interactions:

Before taking DEBIGLIP 100 SR TABLET, inform your doctor if you are taking any of the following medicines:  

Over dosage:

If you or anyone else accidentally takes too much of DEBIGLIP 100 SR TABLET, consult your doctor immediately or visit the nearby hospital. Overdosage symptoms of DEBIGLIP 100 SR TABLET are muscle pain, mild and transient paraesthesia (burning and prickling sensation in hands and legs), fever, oedema (swelling in arms and legs) and laboratory abnormalities such as transient increase in lipase levels, increases in creatine phosphokinase (CPK), aspartate aminotransferase (AST), C-reactive protein (CRP) and myoglobin levels.    

Synopsis

Drug :   Vildagliptin
Pharmacological Category :   Dipeptidyl peptidase-4 (DPP-4) inhibitors
Therapeutic Indication :   Type II diabetes mellitus          
Dosage Forms :   Tablet

More Information

 

 

FAQs About DEBIGLIP 100 SR TABLET

Q: Can DEBIGLIP 100 SR TABLET be used to manage diabetes mellitus?

A: Yes, DEBIGLIP 100 SR TABLET lowers blood glucose levels and it is specifically used to manage type II diabetes mellitus which is a medical condition where the body does not make enough insulin or if the produced insulin that the body makes is not optimal leading to increased blood glucose levels in the body. Consult your doctor before taking DEBIGLIP 100 SR TABLET.

Q: Can I take DEBIGLIP 100 SR TABLET along with other hypoglycemic drugs like metformin or glimepiride?

A: Using DEBIGLIP 100 SR TABLET along with other hypoglycemic drugs like metformin, glimepiride may drastically lower your blood glucose levels. So, be cautious and inform your doctor before taking any other anti-diabetic medicines.

Q: Does taking DEBIGLIP 100 SR TABLET cause weight gain?

A: No, DEBIGLIP 100 SR TABLET has no effect on weight gain. Moreover, these kinds of medicines delay gastric emptying and make you feel satiety (stomach fullness). These further decreases hunger. So, basically DEBIGLIP 100 SR TABLET has no effect or it does not influence weight gain.

Q: How does DEBIGLIP 100 SR TABLET work?

A: DEBIGLIP 100 SR TABLET controls blood glucose level by acting on the pancreas to produce more insulin and less glucagon which leads to low production of blood sugar levels resulting in controlled blood glucose levels.

Q: Does DEBIGLIP 100 SR TABLET cause dizziness?

A: Yes, DEBIGLIP 100 SR TABLET may cause dizziness in some individuals. To manage this effect, lie down until dizziness is gone, then get up slowly. Move slowly and carefully, do not hurry. Get adequate rest. Drink plenty of water and other fluids. Avoid coffee, cigarettes, alcohol and drugs. Consult your doctor if the symptom gets worse.

Q: Can DEBIGLIP 100 SR TABLET be used in children?

A: DEBIGLIP 100 SR TABLET is not recommended for use in children and adolescents up to 18 years of age.

Q: What does DEBIGLIP 100 SR TABLET contain?

A: It contains Vildagliptin which belongs to group of medicines called Oral Anti-diabetics.

References

1. KD. Tripathi. Insulin, Oral Hypoglycaemic Drugs and Glucagon. Essentials of medical pharmacology. Seventh edition. 2013. Page-275.

2. B Ahren, A Schweizer, S Dejager, E B Villhauer, B E Dunning, J E Foley. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. NIH National Library of Medicine. National Center for Biotechnology Information.PubMed.gov. [Revised in September 2011] [Accessed on 16th October 2024] click here

3. Kalyan Kumar Gangopadhyay and Parminder Singh. Consensus Statement on Dose Modifications of Antidiabetic Agents in Patients with Hepatic Impairment. NIH National Library of Medicine. National Center for Biotechnology Information. PMC PubMed Central. [Revised in March 2017] [Accessed on 16th October 2024] click here

4. Novartis Europharm Limited. Electronic Medicines Compendium (EMC) [Revised in August 2023] [Accessed on 16th October 2024] click here

5. Novartis Pharma GmbH. European Medicines Agency (EMA). [Revised in July 2012] [Accessed on 16th October 2024] click here

User Feedback

 

 

Author Details

Written By Srilekha. R - B.Pharm
Reviewed By Dr. Sankara Babu Gorle - MBBS, MD(Pharmacology) View profile
Last updated on 19 Nov 2024 | 04:11 PM(IST)
    Country Of Origin
    India
Disclaimer:

The contents of this website are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. Do not disregard professional medical advice or delay in seeking it because of something you have read on this website.